Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Appointed director
Asset disposition
Class action filed

Cellectar Biosciences, Inc. (CLRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/14/2023 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update FLORHAM PARK, N.J., August 14, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. Second Quarter and Recent Corporate Highlights"
06/29/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Appendix A"
05/04/2023 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update FLORHAM PARK, N.J., May 4, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. First Quarter and Recent Corporate Highlights"
03/09/2023 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update FLORHAM PARK, N.J., Mar. 9, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update. Fourth Quarter and Recent Corporate Highlights"
01/04/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/02/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "AMENDED AND RESTATED BY-LAWS OF",
"DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT"
11/03/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
09/22/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1study of Iopofosine I 131 in Pediatric Brain Tumors FLORHAM PARK, N.J., September 22, 2022 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing Phase 1study of iopofosine I 131 in children and adolescents with inoperable relapsed or refractory high grade gliomas . The grant was awarded by the National Institute of Health’ s National Cancer Institute based upon the initial signals of efficacy in the Phase 1study, which is an international, open-label, dose escalation, safety study. The funding allows for an expansion ..."
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’ s Blood Cancer Journal"
08/05/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
04/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’ s Macroglobulinemia"
03/21/2022 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update FLORHAM PARK, N.J., March 21, 2022 -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2021 and provided a corporate update. Fourth Quarter and Recent Corporate Highlights · Presented data from 11 multiple myeloma patients from the company’ s ongoing Phase 2 CLOVER-1study of iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition. The patients included in this report were triple class refractory had a median 7.2 prior lines of therapy, 50% classified as high risk, showed a mean over..."
03/15/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "2022 N A S D A Q"
02/25/2022 8-K Quarterly results
12/14/2021 8-K Quarterly results
11/16/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cellectar’ s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors FLORHAM PARK, N.J., November 16, 2021 -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in a Phase 1study of iopofosine I-131 in children and adolescents with relapsed and refractory high grade gliomas and soft tissue sarcomas, exhibited positive changes in various tumor parameters. The Phase 1study is an international, open-label, dose escalation, safety study of iopofosine in children and adolescents with relapsed or refractory cancers, specifically HGGs, high risk neuroblastoma and select soft tissue sarcomas. ..."
11/08/2021 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update FLORHAM PARK, N.J., November 8, 2021 -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. Third Quarter and Recent Corporate Highlights · Announced the completion of the Part A portion of a safety and tolerability study of iopofosine I-131 in combination with external beam radiation in relapsed or refractory head and neck cancer. The investigator-initiated study is being conducted by the University of Wisconsin as part of a Specialized Program of Research Excellen..."
11/02/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer"
10/25/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies"
09/22/2021 8-K Quarterly results
09/15/2021 8-K Quarterly results
08/18/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
07/13/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc."
07/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy